A Financial Analysis of a Publicly Traded Health Care Company
| HCM 385 | Jamea Kemple-Calambas | | A Financial Analysis of a Publicly Traded Health Care Company | |
In this paper, I will use financial data and research of a publicly traded healthcare company to give an analysis of the selected company’s financial status. |
The company I selected to analyze is a Biotech and a Cell Therapy healthcare company aptly named NeoStem, inc..
A History of NeoStem
On January 19, 2011, NeoStem acquired Progenitor Cell Therapy, a cell therapy contract manufacturing company serving the industry from licensed, state-of-the art facilities in New Jersey and California. This event added to NeoStem over 100 years of collective experience in the business and science of cell therapy and its development. PCT has performed over 30,000 cell therapy procedures and processed and stored over 18,000 cell therapy products and arranged the logistics and transportation for over 14,000 cell therapy products for clinical use by over 5,000 patients.
The PCT acquisition puts NeoStem in an excellent position as it transitions to cell-based therapeutics. AMR-001 is an autologous stem cell treatment designed to prevent adverse cardiac events following acute myocardial infarction. A Phase II trial for Amorcyte began enrolling patients in January 2012.
Through the PCT acquisition, NeoStem also owns 80% of Athelos Corporation, a company developing a T-cell therapeutic with potential in a range of auto-immune conditions such as graft versus host disease, asthma and diabetes.
NeoStem had a foothold in China since 2009, when the company acquired a controlling interest in Suzhou Erye Pharmaceuticals Ltd., or Erye. Erye has recently built and validated a new manufacturing facility, doubling its capacity and creating capacity within its existing production lines for higher margin products. With the objective of fully focusing its efforts and resources on cell therapeutics, NeoStem divested its 51% ownership of Erye in November 2012.
In 2007,
In this paper, I will use financial data and research of a publicly traded healthcare company to give an analysis of the selected company’s financial status. |
The company I selected to analyze is a Biotech and a Cell Therapy healthcare company aptly named NeoStem, inc..
A History of NeoStem
On January 19, 2011, NeoStem acquired Progenitor Cell Therapy, a cell therapy contract manufacturing company serving the industry from licensed, state-of-the art facilities in New Jersey and California. This event added to NeoStem over 100 years of collective experience in the business and science of cell therapy and its development. PCT has performed over 30,000 cell therapy procedures and processed and stored over 18,000 cell therapy products and arranged the logistics and transportation for over 14,000 cell therapy products for clinical use by over 5,000 patients.
The PCT acquisition puts NeoStem in an excellent position as it transitions to cell-based therapeutics. AMR-001 is an autologous stem cell treatment designed to prevent adverse cardiac events following acute myocardial infarction. A Phase II trial for Amorcyte began enrolling patients in January 2012.
Through the PCT acquisition, NeoStem also owns 80% of Athelos Corporation, a company developing a T-cell therapeutic with potential in a range of auto-immune conditions such as graft versus host disease, asthma and diabetes.
NeoStem had a foothold in China since 2009, when the company acquired a controlling interest in Suzhou Erye Pharmaceuticals Ltd., or Erye. Erye has recently built and validated a new manufacturing facility, doubling its capacity and creating capacity within its existing production lines for higher margin products. With the objective of fully focusing its efforts and resources on cell therapeutics, NeoStem divested its 51% ownership of Erye in November 2012.
In 2007,